Dully, Michele; Brasnett, Christopher; Djeghader, Ahmed; Seddon, Annela; Neilan, John; Murray, David; Butler, James; Soulimane, Tewfik; Hudson, Sarah P. published the artcile< Modulating the release of pharmaceuticals from lipid cubic phases using a lipase inhibitor>, Related Products of 96829-58-2, the main research area is pharmaceutical lipid cubic system controlled release monoglyceride lipase inhibitor; Controlled delivery; Enzyme degradation; Hydrophobic active pharmaceuticals; Lipase inhibitor; Lipid cubic phase; SAXS.
Lipid cubic phase formulations have gained recognition as potential controlled delivery systems for a range of active pharmaceutical and biol. agents on account of their desirable physiochem. properties and ability to encapsulate both hydrophobic and hydrophilic mols. The most widely studied lipid cubic systems are those of the monoacylglycerol lipid family. These formulations are susceptible to lipolysis by a variety of enzymes, including lipases and esterases, which attack the ester bond present on the lipid chain bridging the oleic acid component to the glycerol backbone. The release of poorly soluble mols. residing in the lipid membrane portions of the phase is limited by the breakdown of the matrix; thus, presenting a potential means for further controlling and sustaining the release of therapeutic agents by targeting the matrix stability and its rate of degradation The aims of the present study were twofold: to evaluate an approach to regulate the rate of degradation of lipid cubic phase drug delivery systems by targeting the enzyme interactions responsible for their demise; and to study the subsequent drug release profiles from bulk lipid cubic gels using model drugs of contrasting hydrophobicity. Here, hybrid materials consisting of cubic phases with monoacylglycerol lipids of different chain lengths formulated with a potent lipase inhibitor tetrahydrolipstatin were designed. Modulation of the release of a hydrophobic model pharmaceutical, a clofazimine salt, was obtained by exploiting the matrixes’ enzyme-driven digestion. A stable cubic phase is described, displaying controlled degradation with at least a 4-fold improvement compared to the blank systems shown in inhibitor-containing cubic systems. Sustained release of the model hydrophobic pharmaceutical was studied over 30 days to highlight the advantage of incorporating an inhibitor into the cubic network to achieve tunable lipid release systems. This is done without neg. affecting the structure of the matrix itself, as shown by comprehensive small-angle x-ray scattering experiments
Journal of Colloid and Interface Science published new progress about Biodegradation kinetics. 96829-58-2 belongs to class amides-buliding-blocks, and the molecular formula is C29H53NO5, Related Products of 96829-58-2.
Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics